Orthovisc
AssetAlso hyaluronic acid, Cingal, Emervel, Restylane
Dermal filler providing structural support and tissue augmentation
- Stage
- Phase 3
- Modality
- Other
- Target
- CD44
- 5
- Indications
- 111
- Trials
- 4
- Developers
Indications
5Aesthetic
Phase 3, Completed, NCT02297516, clinicaltrials.gov, 7 Oct 2026
Facial aesthetic treatment
Phase 3, Completed, NCT02297503, clinicaltrials.gov, 7 Oct 2026
Facial wrinkle at the nasolabial folds
Phase 3, Completed, NCT00444626, clinicaltrials.gov, 7 Oct 2026
2 more
In the full profile
- Targets and what it contains2
- Owner and partners4
- Trials111
- Evidence for its targets2
- Competitors1
- Signals13
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 9 sources